Multicenter, randomized, controlled trial of S‐1 monotherapy versus S‐1 and interferon‐α combination therapy for hepatocellular carcinoma with extrahepatic metastases

No effective therapies for extrahepatic metastases from hepatocellular carcinoma (HCC) have yet been identified. Previous studies suggested a potentially promising antitumor effect of combination therapy of S‐1, a novel oral dihydropyrimidine dehydrogenase inhibitor, and interferon (IFN)‐α. The present study aimed to investigate the clinical efficacy of single agent S‐1 and S‐1/IFN‐α for HCC patients with extrahepatic metastases in a randomized, open‐label, multicenter trial.

[1]  M. Kudo,et al.  S-1 versus placebo in patients with sorafenib-refractory advanced hepatocellular carcinoma (S-CUBE): a randomised, double-blind, multicentre, phase 3 trial. , 2017, The lancet. Gastroenterology & hepatology.

[2]  Shuji Takiguchi,et al.  Gastroenterological surgery in Japan: The past, the present and the future , 2017, Annals of gastroenterological surgery.

[3]  Masatoshi Kudo,et al.  Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial , 2017, The Lancet.

[4]  S. Hayami,et al.  Recent trends in hepatectomy for elderly patients with hepatocellular carcinoma , 2014, Surgery Today.

[5]  友國 晃.  miR-146a suppresses the sensitivity to interferon-α in hepatocellular carcinoma cells , 2012 .

[6]  V. Mazzaferro,et al.  EASL-EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma European Association for the Study of the Liver ⇑ , European Organisation for Research and Treatment of Cancer , 2012 .

[7]  H. Eguchi,et al.  miR-146a suppresses the sensitivity to interferon-α in hepatocellular carcinoma cells. , 2011, Biochemical and biophysical research communications.

[8]  H. Ueno,et al.  Phase I/II study of the pharmacokinetics, safety and efficacy of S‐1 in patients with advanced hepatocellular carcinoma , 2010, Cancer science.

[9]  Y. Takeda,et al.  MicroRNA-21 induces resistance to the anti-tumour effect of interferon-α/5-fluorouracil in hepatocellular carcinoma cells , 2010, British Journal of Cancer.

[10]  Y. Takeda,et al.  Insulin-like growth factor-binding protein 7 alters the sensitivity to interferon-based anticancer therapy in hepatocellular carcinoma cells , 2010, British Journal of Cancer.

[11]  Y. Takeda,et al.  Activation of Wnt/β-catenin signalling pathway induces chemoresistance to interferon-α/5-fluorouracil combination therapy for hepatocellular carcinoma , 2009, British Journal of Cancer.

[12]  T. Shirasaka.  Development History and Concept of an Oral Anticancer Agent S-1 (TS-1®): Its Clinical Usefulness and Future Vistas , 2008, Japanese journal of clinical oncology.

[13]  Yoon-Koo Kang,et al.  Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. , 2009, The Lancet. Oncology.

[14]  S. Paggi,et al.  Sorafenib in Advanced Hepatocellular Carcinoma , 2008 .

[15]  Y. Takeda,et al.  Pilot study of combination chemotherapy of S‐1, a novel oral DPD inhibitor, and interferon‐α for advanced hepatocellular carcinoma with extrahepatic metastasis , 2008, Cancer.

[16]  Y. Takeda,et al.  Interferon‐α and 5‐fluorouracil combination therapy after palliative hepatic resection in patients with advanced hepatocellular carcinoma, portal venous tumor thrombus in the major trunk, and multiple nodules , 2007, Cancer.

[17]  Y. Takeda,et al.  Combination therapy of interferon-alpha and 5-fluorouracil inhibits tumor angiogenesis in human hepatocellular carcinoma cells by regulating vascular endothelial growth factor and angiopoietins. , 2007, Oncology reports.

[18]  Y. Takeda,et al.  Patterns and clinicopathologic features of extrahepatic recurrence of hepatocellular carcinoma after curative resection. , 2007, Surgery.

[19]  E. Hatano,et al.  [Retrospective analysis of clinical results in eight patients with advanced hepatocellular carcinoma with lung metastases treated by TS-1]. , 2007, Gan to kagaku ryoho. Cancer & chemotherapy.

[20]  Y. Takeda,et al.  Role of the Fas/FasL pathway in combination therapy with interferon-alpha and fluorouracil against hepatocellular carcinoma in vitro. , 2007, Journal of hepatology.

[21]  Y. Takeda,et al.  Hepatic resection followed by IFN-alpha and 5-FU for advanced hepatocellular carcinoma with tumor thrombus in the major portal branch. , 2007, Hepato-gastroenterology.

[22]  Y. Takeda,et al.  A case of hepatocellular carcinoma with multiple lung, spleen, and remnant liver metastasis successfully treated by combination chemotherapy with the novel oral DPD-inhibiting chemotherapeutic drug S-1 and interferon-α , 2006, Journal of Gastroenterology.

[23]  Y. Takeda,et al.  A case of hepatocellular carcinoma with multiple lung, spleen, and remnant liver metastasis successfully treated by combination chemotherapy with the novel oral DPD-inhibiting chemotherapeutic drug S-1 and interferon-alpha. , 2006, Journal of gastroenterology.

[24]  Liver Cancer Study Group of Japan.  The general rules for the clinical and pathological study of primary liver cancer , 2006, The Japanese journal of surgery.

[25]  H. Eguchi,et al.  Treatment of hepatocellular carcinoma with major portal vein thrombosis by combined therapy with subcutaneous interferon-α and intra-arterial 5-fluorouracil; role of type 1 interferon receptor expression , 2005, British Journal of Cancer.

[26]  H. Eguchi,et al.  Combination of IFN-α and 5-Fluorouracil Induces Apoptosis through IFN-α/β Receptor in Human Hepatocellular Carcinoma Cells , 2005 .

[27]  H. Eguchi,et al.  Partial Contribution of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL)/TRAIL Receptor Pathway to Antitumor Effects of Interferon-α/5-Fluorouracil against Hepatocellular Carcinoma , 2004, Clinical Cancer Research.

[28]  Joon-Oh Park,et al.  Phase II study of doxorubicin and cisplatin in patients with metastatic hepatocellular carcinoma , 2004, Cancer Chemotherapy and Pharmacology.

[29]  M. Makuuchi,et al.  Selection Criteria for Repeat Hepatectomy in Patients With Recurrent Hepatocellular Carcinoma , 2003, Annals of surgery.

[30]  A. Benson,et al.  Oral eniluracil/5-fluorouracil in patients with inoperable hepatocellular carcinoma. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[31]  Y. Imai,et al.  Combined intraarterial 5‐fluorouracil and subcutaneous interferon‐α therapy for advanced hepatocellular carcinoma with tumor thrombi in the major portal branches , 2002, Cancer.

[32]  J. Bruix,et al.  A phase II trial of oral eniluracil/5-fluorouracil in patients with inoperable hepatocellular carcinoma. , 2001, European journal of cancer.

[33]  S. Fan,et al.  Improving Survival Results After Resection of Hepatocellular Carcinoma: A Prospective Study of 377 Patients Over 10 Years , 2001, Annals of surgery.

[34]  F. Kurokawa,et al.  Percutaneous radiofrequency ablation therapy with combined angiography and computed tomography assistance for patients with hepatocellular carcinoma , 2001, Cancer.

[35]  H. Eguchi,et al.  Augmentation of antitumor activity of 5-fluorouracil by interferon alpha is associated with up-regulation of p27Kip1 in human hepatocellular carcinoma cells. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[36]  M. van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.

[37]  M Van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. , 2000, Journal of the National Cancer Institute.

[38]  H. El‐Serag,et al.  Rising incidence of hepatocellular carcinoma in the United States. , 1999, The New England journal of medicine.

[39]  M. Mizumoto,et al.  Results of surgical treatment for recurrent hepatocellular carcinoma; comparison of outcome among patients with multicentric carcinogenesis, intrahepatic metastasis, and extrahepatic recurrence. , 1998, Journal of hepato-biliary-pancreatic surgery.

[40]  M. Fukushima,et al.  Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. , 1996, Anti-cancer drugs.

[41]  E. Lakatos,et al.  Sample sizes based on the log-rank statistic in complex clinical trials. , 1988, Biometrics.

[42]  Y. Morioka,et al.  Hepatic resection for hepatocellular carcinoma. Clinical features and long-term prognosis. , 1987 .

[43]  E. McFadden,et al.  Toxicity and response criteria of the Eastern Cooperative Oncology Group , 1982, American journal of clinical oncology.